LOGIN  |  REGISTER
C4 Therapeutics
Viking Therapeutics

Oscar Health 2024 Second Quarter Conference Call

July 09, 2024 | Last Trade: US$15.89 0.61 3.99

NEW YORK / Jul 09, 2024 / Business Wire / Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, will release its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024.

Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows:

  • Live Call: (888) 596-4244
  • Conference ID: 776-8132
  • Webcast Link

The call will be archived and available on Oscar’s investor relations website (www.ir.hioscar.com) following August 7, 2024 for a period of 90 days.

About Oscar Health

Oscar Health, Inc. (“Oscar”) is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members. At Oscar, our mission is to make a healthier life accessible and affordable for all. Headquartered in New York City, Oscar has been challenging the healthcare system's status quo since our founding in 2012. The company’s member-first philosophy and innovative approach to care has earned us the trust of approximately 1.5 million members, as of April 2024. We offer Individual & Family and Small Group plans, and +Oscar, our full stack technology platform, to others within the provider and payor space. Our vision is to refactor healthcare to make good care cost less. Refactor is a term used in software engineering that means to improve the design, structure, and implementation of the software, while preserving its functionality. At Oscar, we take this definition a step further. We improve our members’ experience by building trust through deep engagement, personalized guidance, and rapid iteration.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page